Comments on investigating leucine-enriched branched-chain amino acid (BCAA) supplementation in elderly chronic kidney disease (CKD) patients
摘要
We comment on Sunsandee et al.'s RCT of leucine-enriched BCAA supplementation in elderly CKD patients. Despite a modest muscle gain, methodological and practical limitations—including unbalanced BCAA formulation, insensitive functional tests, lack of subgroup analysis, and high pill burden—undermine generalizability. Recommendations for future studies are discussed.